Indeed, there is increasing interest in targeting MHC class II-restricted antigens in immunotherapies (102–104) and mutated neoantigens that stimulate anti-tumour CD4+ T cell responses have recently been identified in other syngeneic tumour models (103, 105, 106). Here, CD4 is linked to neoplasm.